House Republicans call for FDA firings after approval of generic abortion pill

House Republicans have called for the firing of senior Food and Drug Administration (FDA) officials after the agency's recent approval of another generic mifepristone abortion pill.

Key Takeaways:

• A group of House Republicans have reacted to the FDA's approval of a new generic abortion pill by calling for top FDA officials to be fired.

• Pro-life groups and others view the move as a betrayal of HHS and FDA's promise to review the abortion pill mifepristone's safety.

• The Trump administration has attempted to explain the generic approval by claiming that they were simply following what is required by law.

The Backstory:

A letter dated September 19 addressed to a group of GOP state attorneys general stated that the FDA planned to review evidence about the safety of mifepristone.

“This Administration will ensure that women’s health is properly protected by thoroughly investigating the circumstances under which mifepristone can be safely dispensed,” Robert F. Kennedy Jr. and FDA Commissioner Marty Makary proclaimed. 

However, last week, the agency authorized a new generic version of mifepristone made by pro-abortion company Evita Solutions LLC, finding the drug “bioequivalent and therapeutically equivalent to” brand name Mifeprex. Previously, Robert F. Kennedy Jr., the current Secretary of Health and Human Services, promised Republican attorneys general that the FDA would organize a review of mifepristone.

The Details:

The FDA’s decision to approve a new generic abortion pill has upset pro-life groups and lawmakers, who have castigated the move as a betrayal of the promise made by Secretary Kennedy and Makary to review the safety of the abortion pill in light of new research and analyses pointing to a much higher adverse event rate than currently listed on the FDA label. 

A group of Republican lawmakers — spearheaded by Rep. Mark Harris of North Carolina, a vocal pro-life advocate — penned a letter to HHS Secretary Robert F. Kennedy Jr., requesting that the director of the Office of Generic Drugs, the director of the Center for Drug Evaluation and Research, and “other bureaucrats responsible for this reckless decision” be ousted from their posts, according to a report from media outlet Notus. 

“This approval is particularly alarming given that just weeks prior… you publicly announced that the FDA would undertake a thorough review of the safety of abortion pills,” the House Republicans — including Reps. Josh Brecheen, Keith Self, Eli Crane, Paul Gosar, Chip Roy, Mary Miller, Andy Biggs, Barry Moore, Scott Perry, and Ralph Norman — stated in the letter. “The approval of a generic version of this dangerous drug not only contradicts the announced review, but also runs directly counter to this Administration’s stated pro-life agenda.”

Commentary:

Pro-lifers React

Live Action founder and president Lila Rose called the decision a "reckless and harmful mistake," in a press release, adding that "Mifepristone was developed solely to kill babies and in that process they often harm mothers." She called for the FDA to "reverse this decision immediately." 

Similarly, Kristi Hamrick, a spokeswoman for Students for Life of America, stated in an interview with The Washington Post, “This is a wildly disappointing decision. We are extraordinarily disappointed. This has to be addressed.” 

Mike Pence, Trump’s former vice president, even lambasted the FDA’s move as a “total betrayal” of pro-life voters who helped to elect Trump as president for a second term. 

Trump Administration Attempts to Explain

Reacting to pro-life backlash after the FDA move, Robert F. Kennedy Jr. posted a tweet, claiming that “federal law requires approval when an application proves the generic is identical to the brand-name drug,” maintaining that the FDA’s review was still underway. “The Biden administration removed mifepristone’s in-person dispensing rule without studying the safety risks. We are filling that gap," he said. "Recent studies already point to serious risks when mifepristone is used without proper medical oversight,” he added. 

HHS spokesman Andrew Nixon reinforced the notion that the FDA “has very limited discretion in deciding whether to approve a generic drug,” repeating the claim that the agency will be “conducting a study of the reported adverse effects of mifepristone to ensure the FDA’s risk mitigation program for the drug is sufficient to protect women from unstated risks." Nixon added, "The FDA does not endorse any drug product and directs prescribers to follow all labeling.”

White House press secretary Karoline Leavitt asserted during a press briefing on October 3 that the FDA’s generic approval was “not an endorsement of this drug by any means” and that “they are just simply following the law.”

But for pro-lifers in the US and beyond, the latest FDA decision is arguably a litmus test of the Trump administration’s fidelity to its pledges to defend life as well as the welfare of mothers and preborn children over anti-life ideologies.

The Bottom Line:

This incident spotlights the ongoing conflict between pro-life voters and federal agencies, as even a Republican administration with a cumbersome bureaucracy could put life-affirming policymaking on the back burner.

At this juncture, pro-lifers should embrace vigilance and strategic advocacy to continue defending the sanctity of all human lives in the midst of attempts to widen abortion access, even from the top echelons of power.